late
widespread
opinion
era
infecti
diseas
finish
vaccin
antibiot
control
microbi
pathogen
inde
commonli
believ
discov
import
agent
infect
littl
left
scientif
field
war
infecti
diseas
often
repeat
conclus
yet
quarter
centuri
previous
unrecogn
pathogen
discov
etiolog
agent
human
infecti
diseas
tabl
diseas
well
character
caus
unknown
novel
syndrom
recogn
etiolog
agent
identifi
includ
acquir
immunodefici
syndrom
aid
human
immunodefici
viru
hiv
nevertheless
gener
belief
infecti
diseas
less
import
cardiovascular
diseas
cancer
favor
research
support
public
health
attent
concept
emerg
infecti
diseas
defin
brought
attent
physician
scientist
wide
distribut
read
public
institut
medicin
nation
academi
scienc
emerg
infect
microbi
threat
health
unit
state
emerg
least
novel
infecti
agent
follow
year
tabl
emphas
phenomenon
would
continu
seri
event
caus
awar
presenc
unknown
pathogen
abrupt
onset
cluster
sever
ill
eg
legionella
pneumonia
convent
american
legion
recognit
distinct
gross
microscop
patholog
lesion
eg
pseudomembran
coliti
caus
clostridium
difficil
clinic
laboratori
microscopi
eg
intramonocyt
inclus
ehrlichia
chaffeensi
patient
human
monocytotrop
ehrlichiosi
numer
instanc
applic
advanc
technolog
method
identifi
etiolog
welldefin
syndrom
eg
norovirus
norwalk
diarrheal
ill
outbreak
occur
sampl
retain
year
earlier
mani
method
employ
initi
detect
identif
novel
emerg
pathogen
includ
microscopi
bacteri
cultur
cell
cultur
anim
inocul
electron
microscopi
archaic
serolog
test
crossreact
serolog
test
serendipit
serolog
test
immunohistochemistri
howev
current
molecular
method
includ
probe
hybrid
polymeras
chain
reaction
pcr
amplifi
target
signal
nucleic
acid
sequenc
promin
method
detect
character
newli
emerg
pathogen
discov
agent
determin
truli
novel
exampl
applic
molecular
method
identif
previous
unidentifi
agent
human
infect
hepat
c
viru
hcv
discoveri
hepat
b
virus
clear
major
case
posttransfus
hepat
due
condit
design
nona
nonb
hepat
diseas
transmiss
chimpanze
plasma
infect
chimpanze
pellet
ultracentrifug
nucleic
acid
extract
pellet
cdna
synthes
rna
dna
random
primer
revers
transcriptas
screen
identifi
rnaencod
clone
express
antigen
react
antibodi
infect
subject
eventu
complet
genom
genotyp
hcv
determin
novel
speci
close
relat
flavivirus
establish
anoth
dramat
emerg
viral
diseas
occur
four
corner
region
southwestern
unit
state
mysteri
highli
lethal
respiratori
ill
investig
team
center
diseas
control
prevent
cdc
extens
serolog
screen
numer
antigen
reveal
unexpect
reactiv
antigen
hantavirus
part
world
caus
renal
diseas
hemorrhag
fever
immunohistochemistri
detect
hantavir
antigen
pulmonari
endothelium
region
within
segment
rna
hantavir
genom
encod
protein
highli
conserv
target
primer
nest
pcr
revers
transcriptas
gener
cdna
tissu
infect
patient
analyz
pcr
product
sequenc
reveal
novel
hantaviru
subsequ
name
sin
nombr
viru
viral
sequenc
identifi
patient
peromyscu
maniculatu
rodent
reservoir
stori
hantavir
pulmonari
syndrom
unfold
reveal
relat
agent
mani
locat
north
central
south
america
novel
coronaviru
associ
case
sever
acut
respiratori
syndrom
sarscov
emerg
southern
china
late
spread
countri
five
contin
confirm
case
death
case
report
sinc
juli
rtpcr
clone
sequenc
contribut
identif
sarscov
within
week
first
case
report
enabl
rapid
develop
effect
molecular
diagnost
assay
routin
clinic
use
sarscov
associ
high
mortal
thu
time
accur
diagnosi
need
prevent
spread
contagi
diseas
sarscov
spread
respiratori
secret
airborn
transmiss
earli
ill
sar
distinguish
common
respiratori
infect
base
clinic
symptom
sar
epidem
pcrbase
molecular
test
help
abil
rapidli
screen
mani
virus
identif
sarscov
specif
rtpcr
serolog
assay
develop
rtpcr
detect
infect
appear
antibodi
risk
transmiss
greatest
bacteri
rr
gene
encod
rrna
recogn
valuabl
phylogenet
tool
discrimin
identif
bacteri
speci
david
relman
craft
tool
approach
identifi
unknown
etiolog
agent
pcr
rr
gene
primer
correspond
genom
region
conserv
among
eubacteria
use
approach
amplifi
determin
bacteri
dna
sequenc
bacillari
angiomatosi
lesion
patient
aid
comparison
bacteri
gene
databas
reveal
dna
sequenc
match
bacteria
current
name
bartonella
hensela
b
quintana
serendipit
test
patient
also
diagnos
cat
scratch
diseas
led
recognit
b
hensela
also
long
soughtaft
etiolog
wellcharacter
diseas
approach
discoveri
use
rr
gene
amplif
dna
sequenc
led
identif
current
classifi
anaplasma
phagocytophilum
etiolog
agent
ticktransmit
human
granulocytotrop
anaplasmosi
subsequ
ehrlichia
ewingii
recogn
anoth
human
tickborn
pathogen
among
patient
evalu
molecular
diagnost
laboratori
test
neg
e
chaffeensi
infect
recent
bobbi
pritt
mayo
clinic
note
melt
curv
dna
amplicon
realtim
pcr
assay
anaplasmatacea
differ
expect
curv
known
pathogen
group
patient
wisconsin
minnesota
sequenc
analysi
identifi
anoth
novel
tickborn
pathogen
tent
design
ehrlichia
murislik
agent
discoveri
novel
bunyaviru
caus
thousand
human
infect
case
fatal
rate
provinc
china
reli
upon
molecular
approach
identifi
viral
agent
xueji
yu
investig
outbreak
china
thought
due
sever
infect
phagocytophilum
note
clinic
manifest
differ
anaplasmosi
observ
cytopath
effect
cell
inocul
clinic
sampl
rather
typic
morula
form
anaplasma
speci
infect
cell
ultrastructur
analysi
suggest
pathogen
caus
outbreak
viru
belong
famili
bunyavirus
base
known
sequenc
bunyavirus
pcr
primer
design
yield
amplicon
subsequ
began
sequenc
rna
heavili
infect
cell
discard
sequenc
cultur
host
speci
cani
familiari
approach
enabl
determin
recov
novel
phleboviru
famili
bunyavirida
accomplish
feat
without
use
nextgener
sequenc
ng
applic
ng
allow
us
obtain
abund
viral
gene
sequenc
infect
host
cell
discoveri
novel
viral
bacteri
agent
molecular
technolog
critic
initi
discoveri
agent
emerg
infecti
diseas
method
also
routin
use
character
pathogen
strain
sequenc
variat
molecular
data
wide
use
molecular
epidemiolog
studi
phylogenet
analys
sequenc
comparison
perform
facilit
specif
detect
genet
divers
strainssequ
investig
origin
transmiss
distribut
biolog
divers
pathogen
fundament
import
prevent
track
diseas
outbreak
knowledg
sequenc
variat
use
develop
accur
diagnost
assay
design
effect
treatment
strategi
diseas
caus
agent
molecular
epidemiolog
studi
critic
public
health
surveil
provid
exampl
molecular
test
contribut
public
health
surveil
patient
care
continu
challeng
influenza
includ
sporad
human
case
highli
pathogen
avian
influenza
emerg
pandem
influenza
human
infect
avian
influenza
influenza
viru
undergo
continu
antigen
drift
sporad
antigen
shift
viral
surfac
glycoprotein
hemagglutinin
h
neuraminidas
n
influenza
h
n
subtyp
antigen
h
n
subtyp
human
lack
immun
introduc
reassort
viru
gene
caus
pandem
wherea
h
n
antigen
variant
determin
point
mutat
caus
season
influenza
epidem
molecular
assay
prefer
method
identif
surveil
new
strain
influenza
infect
influenza
pathognomon
symptom
diagnosi
base
clinic
sign
correct
twothird
patient
therefor
sensit
rapid
laboratori
test
requir
diagnos
guid
antivir
treatment
recent
multiplex
molecular
assay
respiratori
virus
includ
influenza
virus
develop
sever
receiv
approvalclear
us
food
drug
administr
fda
routin
clinic
use
tabl
list
pandem
influenza
viru
assay
provid
rapid
sensit
test
respiratori
viral
infect
human
immunodefici
viru
discov
tabl
singlestrand
positivesens
envelop
rna
retroviru
http
wwwhivlanlgov
caus
aid
chronic
diseas
lead
immunodefici
suscept
opportunist
infect
http
wwwwhoint
hiven
three
group
identifi
base
sequenc
similar
includ
main
outlier
n
nonmnono
http
wwwhivlanl
gov
three
group
group
domin
global
epidem
classifi
subtyp
b
c
f
g
h
j
k
addit
circul
recombin
form
crf
mosaic
virus
form
subtyp
coor
superinfect
also
recogn
http
wwwhiv
lanlgov
although
subtyp
b
predomin
north
america
europ
nonb
variant
repres
circul
global
recent
year
preval
nonb
subtyp
crf
unit
state
steadili
increas
due
increas
intern
travel
immigr
sequenc
data
genom
use
track
hiv
epidem
design
accur
viral
detect
viral
load
drugresist
genotyp
assay
guid
clinic
use
antiretrovir
treatment
recent
avail
ng
approach
greatli
facilit
gener
sequenc
detect
quasispeci
improv
understand
infect
pathogenesi
epidem
believ
million
peopl
worldwid
infect
hcv
http
peopl
infect
hcv
develop
chronic
infect
chronic
hepat
c
close
associ
develop
cirrhosi
hepatocellular
carcinoma
common
caus
adult
liver
transplant
unit
state
world
http
wwwcdcgovhepatitishcv
comparison
hcv
genom
sequenc
around
world
reveal
substanti
heterogen
nucleotid
sequenc
phylogenet
analys
shown
hcv
strain
classifi
six
genotyp
number
larg
number
subtyp
within
genotyp
hcv
genotyp
appear
worldwid
distribut
rel
preval
vari
one
geograph
area
anoth
hcv
genotyp
report
common
unit
state
hcv
viru
genom
sequenc
use
studi
hcv
genotyp
subtyp
quasispeci
mutat
inform
import
epidemiolog
studi
trace
sourc
infect
develop
direct
act
antivir
daa
therapi
understand
suscept
resist
antivir
treatment
mani
method
employ
clinic
diagnost
emerg
pathogen
includ
microscopi
bacteri
cultur
cell
cultur
serolog
test
howev
method
limit
must
consid
clinic
laboratori
exampl
even
though
cell
cultur
could
consid
gold
standard
diagnosi
infect
emerg
oblig
intracellular
bacteria
rickettsia
ehrlichia
requir
biolog
safeti
laboratori
level
rickettsia
ehrlichia
make
test
difficult
implement
mani
convent
clinic
microbiolog
laboratori
prolong
turnaround
time
tat
eg
detect
cultur
day
sampl
process
make
approach
impract
result
test
clinic
use
due
failur
guid
therapi
earli
stage
infect
appropri
antibiot
treatment
highli
effect
similar
cultur
serolog
test
indirect
immunofluoresc
assay
reli
detect
antigenspecif
antibodi
sever
limit
low
sensit
earli
stage
infect
low
level
specif
antibodi
falseposit
result
due
crossreact
antibodi
antigen
closelyrel
bacteri
speci
addit
diagnosi
acut
infect
igg
serolog
use
singl
pair
acut
convalesc
serum
sampl
limit
lack
standard
cutoff
titer
among
laboratori
singl
sampl
obtain
frequent
inabl
obtain
convalesc
serum
pair
sampl
requir
latter
case
igg
serolog
could
use
epidemiolog
surveil
pair
sera
optim
time
diagnosi
treatment
acut
infect
thu
emerg
molecular
method
includ
probe
hybrid
target
signal
amplif
sequenc
provid
better
diagnost
advantag
compar
microscopi
cultur
serolog
rapid
tat
higher
sensit
higher
specif
differ
patient
popul
use
differ
specimen
type
eg
blood
plasma
cerebrospin
fluid
tissu
fluid
molecular
test
becom
gold
standard
due
high
neg
posit
predict
valu
abil
detect
character
newli
emerg
pathogen
clinic
purpos
molecular
assay
routin
use
clinic
diagnosi
prognosi
treatment
decis
variou
emerg
infecti
diseas
tabl
tabl
us
fdaapprovedclear
test
pathogen
cdc
test
agent
also
laboratorydevelop
test
brought
clinic
use
signific
research
develop
valid
studi
individu
laboratori
infecti
diseas
clinic
molecular
test
emerg
infecti
diseas
includ
nucleic
acid
detect
assay
defin
limit
detect
cutoff
quantit
method
broad
dynam
rang
lower
higher
limit
quantif
valu
genotyp
subtyp
assay
drug
resist
mutat
assay
even
singl
basepair
resolut
use
diseas
prognosi
guid
treatment
strategi
gener
qualiti
manag
protocol
cover
preanalyt
analyt
postanalyt
phase
also
appli
molecular
test
emerg
pathogen
follow
discoveri
hcv
molecular
test
develop
implement
routin
clinic
use
detect
viral
infect
monitor
viral
load
examin
specif
drugresist
mutat
hcv
genotyp
guid
patient
manag
sever
practic
guidelin
incorpor
hcv
molecular
test
eg
http
wwwwhointhivpubguidelinesen
http
wwwhcvguidelinesorgfullreportview
exampl
detect
hcv
rna
igg
antibodi
diagnost
current
hcv
infect
hcv
genotyp
difficult
treat
genotyp
test
hcv
genotyp
recommend
guid
select
appropri
treatment
regimen
hcv
rna
detect
genotyp
assay
routin
perform
clinic
diagnost
laboratori
http
wwwhcvguidelinesorgfullreportview
year
advanc
molecular
technolog
hcv
clinic
molecular
test
improv
significantli
respect
perform
characterist
includ
sensit
specif
dynam
rang
current
sever
fdaapprovedclear
molecular
test
hcv
tabl
new
method
continu
develop
evalu
better
care
patient
hcv
infect
high
portion
emerg
infecti
diseas
vectorborn
zoonos
emerg
natur
cycl
underli
caus
emerg
combin
environment
chang
increas
popul
geograph
distribut
reservoir
host
vector
develop
new
scientif
tool
contribut
detect
identif
exampl
pcrbase
molecular
method
enabl
discoveri
larg
number
bacteri
viral
organ
tick
preced
identif
organ
etiolog
agent
emerg
infecti
diseas
among
emerg
infecti
diseas
two
contrast
tickborn
infect
lyme
borreliosi
human
monocytotrop
ehrlichiosi
hme
lyme
diseas
well
known
fear
time
inappropri
diagnos
rare
fatal
hme
larg
unknown
frequent
misdiagnos
anoth
tickborn
diseas
rocki
mountain
spot
fever
viral
infect
often
lifethreaten
lyme
borreliosi
occur
particularli
suburban
popul
northeastern
unit
state
investig
extens
promin
academ
medic
institut
region
hme
occur
particularli
rural
southeastern
unit
state
focu
indepth
clinic
studi
academ
medic
center
region
lyme
borreliosi
hme
high
incid
although
hme
well
recogn
effect
condit
develop
applic
diagnost
test
includ
molecular
diagnost
far
satisfi
diagnosi
lyme
borreliosi
depend
heavili
serolog
assay
patient
lyme
diseas
frequent
develop
antibodi
borrelia
burgdorferi
time
cours
ill
present
medic
attent
patient
classic
bullsey
appear
rash
diagnos
treat
effect
appropri
antibiot
recov
infect
antibodi
take
time
stimul
produc
thu
patient
diagnos
may
delay
molecular
method
seldom
provid
diagnosi
owe
pauciti
organ
blood
readili
obtain
clinic
sampl
tremend
problem
larg
number
person
atyp
symptom
wide
rang
includ
similar
chronic
fatigu
syndrom
fibromyalgia
convinc
suffer
chronic
lyme
diseas
whose
result
valid
test
support
diagnosi
mani
convinc
test
inadequ
better
test
need
contrast
patient
hme
often
develop
antibodi
etiolog
agent
e
chaffeensi
time
present
medic
attent
bacteria
infect
mononuclear
phagocyt
present
circul
monocyt
provid
often
effect
target
molecular
diagnost
time
appropri
antibiot
treatment
result
rapid
recoveri
otherwis
lifethreaten
infect
yet
hme
like
incid
similar
lyme
diseas
lack
readili
avail
pointofcar
diagnost
test
effect
molecular
target
gene
identifi
inhous
assay
provid
proofofconcept
molecular
diagnost
offer
effect
approach
moreov
lowcost
instrumentfre
devic
nucleic
acid
amplif
specif
identif
develop
would
appropri
pointofcar
diagnosi
effect
effort
made
devis
develop
commerci
molecular
approach
two
import
emerg
infect
lyme
borreliosi
molecular
diagnost
may
possess
solut
borrelia
present
hme
issu
lie
realm
clinic
practic
public
health
busi
physician
unawar
hme
note
febril
ill
tick
season
often
respond
doxycyclin
therapi
inclin
order
send
test
would
cost
patient
serolog
base
compar
igg
antibodi
level
pair
sera
often
fail
provid
diagnosi
acut
infect
reli
seldomobtain
convalesc
serum
public
health
agenc
powerless
address
effect
diseas
diagnos
diagnos
report
epidemiolog
report
depend
data
obtain
passiv
surveil
fact
activ
prospect
populationbas
surveil
endem
region
missouri
suggest
hme
highli
preval
diseas
combin
nonspecif
clinic
manifest
hme
test
underutil
lack
gold
standard
test
effect
therapeut
decis
made
problem
interpret
diagnost
test
serolog
mislead
epidemiolog
data
account
report
low
incid
hme
situat
fail
stimul
interest
commerci
develop
market
use
pointofcar
assay
although
could
adequ
pull
potenti
user
test
advanc
sequenc
technolog
nanotechnolog
bioinformat
driven
molecular
test
includ
assay
emerg
pathogen
comprehens
precis
exampl
avail
variou
sequenc
databas
permit
quick
identif
sequenc
ident
variat
exampl
hiv
databas
http
wwwhivlanlgov
contain
data
hiv
genet
sequenc
drug
resist
associ
mutat
valuabl
hiv
epidemiolog
studi
research
develop
clinic
valid
studi
hiv
clinic
assay
well
known
signific
variat
clinic
phenotyp
presenc
emerg
infect
rang
asymptomat
carrier
lethal
infect
recent
assay
examin
multipl
pathogen
panel
develop
increas
diagnost
yield
mani
pathogen
critic
need
emerg
pathogen
analysi
quicker
easier
costeffect
assay
use
pointofcar
set
new
assay
perform
platform
small
footprint
detect
pathogen
quickli
minut
instead
hour
day
enter
clinic
use
exampl
filmarray
biofir
diagnost
inc
simplexa
focu
diagnost
inc
molecular
assay
gener
result
approxim
min
userfriendli
aler
aler
inc
coba
liat
roch
molecular
system
platform
compact
portabl
gener
rapid
molecular
result
min
use
electr
recharg
batteri
therefor
complet
mobil
suit
pointofcar
test
obviou
current
rapid
develop
new
technolog
enhanc
util
molecular
diagnost
variou
emerg
infecti
diseas
advanc
molecular
method
emerg
infect
come
handinhand
area
includ
gener
infecti
diseas
genet
genom
oncolog
need
develop
unifi
sequenc
databas
input
search
emerg
pathogen
sequenc
understand
pathogengenotypesequ
correl
phenotyp
eg
lethal
carrier
emerg
infect
develop
panel
effect
diagnos
patient
base
share
clinic
sign
symptom
develop
pointofcar
molecular
platform
assay
emerg
infecti
diseas
last
two
decad
sequenc
technolog
evolv
laborintens
timeconsum
methodolog
automat
realtim
sequenc
detect
recent
develop
use
ng
revolution
landscap
microbiolog
infecti
diseas
avail
sequenc
data
speed
pathogen
discoveri
also
help
improv
diagnosi
type
pathogen
detect
virul
drug
resist
develop
new
vaccin
target
treatment
everextend
use
ng
varieti
clinic
sampl
rapid
progress
determin
composit
human
microbiom
impact
upon
human
health
expect
come
year
delug
sequenc
data
requir
consolid
curat
databas
input
search
sequenc
sequenc
variat
associ
symptom
diseas
avail
test
treatment
option
unifi
report
guidelin
molecular
epidemiolog
propos
recent
adopt
guidelin
research
clinic
commun
help
integr
effort
comprehens
genom
metagenom
relev
field
medic
microbiolog
improv
manag
infecti
diseas
tradit
pathogen
detect
method
infecti
diseas
reli
upon
identif
agent
associ
particular
clinic
syndrom
avail
signific
amount
sequenc
inform
emerg
field
metagenom
use
ng
potenti
revolution
pathogen
detect
allow
simultan
detect
microorgan
clinic
sampl
without
priori
knowledg
ident
identifi
new
sequenc
organ
may
initi
consid
nonpathogen
may
caus
infect
differ
human
popul
health
condit
may
caus
diseas
previous
thought
microbi
compon
method
may
determin
previous
unknown
etiolog
infect
exampl
infect
certain
emerg
pathogen
may
caus
diseas
symptom
patient
aid
immun
suppress
organ
transplant
travel
previous
expos
agent
biolog
clinic
studi
necessari
categor
sequenc
inform
interpret
clinic
relev
pathogen
sequenc
detect
critic
diagnosi
treatment
public
health
surveil
emerg
infecti
diseas
assay
examin
multipl
pathogen
panel
develop
assay
design
either
detect
mani
infect
caus
similar
symptom
eg
fdaapprovedclear
respiratori
viral
panel
list
tabl
multipl
virus
trigger
gastrointestin
symptom
pathogen
share
homolog
sequenc
exampl
rrna
sequenc
expect
occur
circumst
biothreat
avail
pathogen
sequenc
understand
correl
clinic
symptom
necessari
ration
design
panel
fit
variou
need
new
technolog
develop
includ
microfluid
nanotechnolog
labonachip
technolog
enabl
develop
userfriendli
easi
quick
pointofcar
molecular
test
includ
aler
aler
inc
coba
liat
roch
molecular
system
set
emerg
infecti
diseas
rapid
accur
identif
caus
agent
critic
facilit
effect
patient
manag
enabl
prompt
initi
infect
control
pointofcar
assay
especi
need
resourcelimit
set
situat
lack
access
central
medic
facil
develop
pointofcar
molecular
test
emerg
pathogen
critic
time
diagnosi
treatment
subsequ
control
emerg
infecti
diseas
